Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Neonatal

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Serious adverse events maximum · newborns with late‐onset sepsis

It is very uncertain whether meropenem changes serious adverse events maximum compared with standard care (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 1.54 [0.9, 2.66]
1 study · 271 participants
Very low

Neurological developmental impairment maximum · newborns with late‐onset sepsis

It is very uncertain whether meropenem changes neurological developmental impairment maximum compared with standard care (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.87 [0.51, 1.48]
1 study · 271 participants
Very low

Necrotising enterocolitis maximum · newborns with late‐onset sepsis

It is very uncertain whether meropenem changes necrotising enterocolitis maximum compared with standard care (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.68 [0.33, 1.42]
1 study · 271 participants
Very low

All‐cause mortality maximum · newborns with late‐onset sepsis

It is very uncertain whether meropenem changes all‐cause mortality maximum compared with standard care (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 1.42 [0.56, 3.62]
1 study · 271 participants
Very low